

1 **Title: The *NR5A1/SF-1* variant p.Gly146Ala cannot explain the phenotype of individuals with a**  
2 **difference of sex development.**

3  
4 Idoia Martinez de Lapiscina<sup>1,2,3,4,5,6</sup>, Chrysanthi Kouri<sup>1,2,7</sup>, Josu Aurrekoetxea<sup>8,9</sup>, Mirian Sanchez<sup>3</sup>, Rawda  
5 Naamneh Elzenaty<sup>1,2,7</sup>, Kay-Sara Sauter<sup>1,2</sup>, Núria Camats<sup>5,10</sup>, Gema Grau<sup>3,6,11</sup>, Itxaso Rica<sup>3,4,5,6,11</sup>, Amaia  
6 Rodriguez<sup>3,11</sup>, Amaia Vela<sup>3,4,5,6,11</sup>, Alicia Cortazar<sup>4,12</sup>, M. Concepción Alonso-Cerezo<sup>13</sup>, Pilar Bahillo<sup>14</sup>,  
7 Laura Berthod<sup>15</sup>, Isabel Esteva<sup>16</sup>, Luis Castaño<sup>3,4,5,6,9,11,\*</sup>, Christa E. Flück<sup>1,2,\*</sup>

8  
9 <sup>1</sup>Pediatric Endocrinology, Diabetology and Metabolism, Department of Pediatrics, Inselspital, Bern  
10 University Hospital, University of Bern, Bern, Switzerland. <sup>2</sup>Department for BioMedical Research,  
11 University of Bern, Bern, Switzerland. <sup>3</sup>Research into the genetics and control of diabetes and other  
12 endocrine disorders, Biocruces Bizkaia Health Research Institute, Cruces University Hospital,  
13 Barakaldo, Spain. <sup>4</sup>CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto  
14 de Salud Carlos III, Madrid, Spain. <sup>5</sup>CIBER de Enfermedades Raras (CIBERER), Instituto de Salud Carlos  
15 III, Madrid, Spain. <sup>6</sup>Endo-ERN, Amsterdam, The Netherlands. <sup>7</sup>Graduate School for Cellular and  
16 Biomedical Sciences, University of Bern, Bern, Switzerland. <sup>8</sup>Research group of Medical Oncology,  
17 Biocruces Bizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain. <sup>9</sup>University  
18 of the Basque Country (UPV-EHU), Leioa, Spain. <sup>10</sup>Growth and Development group, Vall d'Hebron  
19 Research Institute (VHIR), Hospital Universitari Vall d'Hebron, Barcelona, Spain. <sup>11</sup>Department of  
20 Pediatric Endocrinology, Cruces University Hospital, Barakaldo Spain. <sup>12</sup>Endocrinology Department,  
21 Cruces University Hospital, Barakaldo, Spain. <sup>13</sup>La Princesa University Hospital, Madrid, Spain.  
22 <sup>14</sup>Pediatric Endocrinology Unit, Department of Pediatrics, Clinic University Hospital of Valladolid,  
23 Valladolid, Spain. <sup>15</sup>Pediatric Endocrinology Department, Marques de Valdecilla University Hospital,  
24 Santander, Spain. <sup>16</sup>Endocrinology Section, Gender Identity Unit, Regional University Hospital of  
25 Malaga, Malaga, Spain.

26 \*Co-last authors

27

28 Corresponding author: Idoia Martinez de Lapiscina, PhD; [idoia.martinezdelapiscina@unibe.ch](mailto:idoia.martinezdelapiscina@unibe.ch)

29 Phone Nr: +41316641475

30

31 **Short title:** Role of *NR5A1/SF-1* p.Gly146Ala in DSD

32

33

34 **Abstract**

35 Steroidogenic factor 1 (SF-1, *NR5A1*) plays an important role in human sex development. Variants of  
36 *NR5A1*/SF-1 may cause mild to severe differences of sex development (DSD) or may be found in  
37 healthy carriers. So far, the broad DSD phenotypic variability associated *NR5A1*/SF-1 variants remains  
38 a conundrum. The *NR5A1*/SF-1 variant c.437G>C/p.Gly146Ala is common in individuals with a DSD and  
39 has been suggested to act as a susceptibility factor for adrenal disease or cryptorchidism. However, as  
40 the allele frequency in the general population is high, and as functional testing of the p.Gly146Ala  
41 variant *in vitro* revealed inconclusive results, the disease-causing effect of this variant has been  
42 questioned. However, a role as a disease modifier in concert with other gene variants is still possible  
43 given that oligogenic inheritance has been described in patients with *NR5A1*/SF-1 gene variants.  
44 Therefore, we performed next generation sequencing in DSD individuals harboring the *NR5A1*/SF-1  
45 p.Gly146Ala variant to search for other DSD-causing variants. Aim was to clarify the function of this  
46 variant for the phenotype of the carriers. We studied 14 pediatric DSD individuals who carried the  
47 p.Gly146Ala variant. Panel and whole-exome sequencing was performed, and data were analyzed with  
48 a specific data filtering algorithm for detecting variants in *NR5A1*- and DSD-related genes. The  
49 phenotype of the studied individuals ranged from scrotal hypospadias and ambiguous genitalia in  
50 46,XY DSD to typical male external genitalia and ovotestes in 46,XX DSD patients. Patients were of  
51 African, Spanish, and Asian origin. Of the 14 studied subjects, five were homozygous and nine  
52 heterozygous for the *NR5A1*/SF-1 p.Gly146Ala variant. In ten subjects we identified either a clearly  
53 pathogenic DSD gene variant (e.g. in *AR*, *LHCGR*) or one to four potentially deleterious variants that  
54 likely explain the observed phenotype alone (e.g. in *FGFR3*, *CHD7*, *ADAMTS16*). Our study shows that  
55 most individuals carrying the *NR5A1*/SF-1 p.Gly146Ala variant, harbor at least one other deleterious  
56 gene variant which can explain the DSD phenotype. This finding confirms that the p.Gly146Ala variant  
57 of *NR5A1*/SF-1 may not contribute to the pathogenesis of DSD and qualifies as a benign polymorphism.  
58 Thus, individuals, in whom the *NR5A1*/SF-1 p.Gly146Ala gene variant has been identified as the  
59 underlying genetic cause for their DSD in the past, should be re-evaluated with a next-generation  
60 sequencing method to reveal the real genetic diagnosis.

61

## 62 **Introduction**

63 Typical sex development depends on the specific interactions of many genes and pathways in a  
64 defined spatiotemporal sequence. Any perturbation in this very complex biological event, which  
65 involves genetic and hormonal processes, may result in atypical sex development and leads to a broad  
66 range of differences of sex development (DSD) in humans, also known as variations of sex  
67 characteristics (VSC) (1). The *NR5A1* gene, which encodes the steroidogenic factor 1 (SF-1), regulates  
68 multiple genes implicated in adrenal development, gonadal determination and differentiation,  
69 steroidogenesis, and reproduction (2). Since the identification of the first *NR5A1*/SF-1 variation in a  
70 46,XY patient with primary adrenal failure and complete gonadal dysgenesis (3), the gonadal and  
71 reproductive phenotype associated with *NR5A1*/SF-1 variants has broadened including 46,XY and  
72 46,XX cases with sex reversal to minor untypicalities such as hypospadias or even healthy carriers,  
73 whereas adrenal failure has only been found in very rare cases (4, 5).

74 Currently, 291 different *NR5A1*/SF-1 variants are reported in the Human Gene Mutation Database  
75 (HGMD, October 2022). Variants include missense/nonsense, indels, small insertions/deletions,  
76 complete gene deletions or splice-site variants that are scattered throughout the whole gene without  
77 obvious hot spots. According to ACMG (American College of Medical Genetics and Genomics)  
78 classification (6), described variants may qualify as (likely) pathogenic or (likely) benign, and several  
79 are variants of unknown significance (VUS).

80 The nonsynonymous *NR5A1*/SF-1 c.437G>C/p.Gly146Ala (rs1110061) variant has been first described  
81 in a group of Japanese patients presenting with a series of adrenal diseases such as Cushing's  
82 syndrome or non-functioning adrenocortical adenoma (7). In this context, WuQiang et al. reported  
83 that the p.Gly146Ala variant slightly impairs the transactivation ability of adrenal and ovary specific  
84 gene promoters but does not affect cofactor interaction and cellular localization (7). Later, it has been  
85 proposed to act as a susceptibility factor for cryptorchidism (8), isolated micropenis (9, 10),  
86 spermatogenic failure (11, 12), primary ovarian insufficiency (POI) (13) and type 2 diabetes (14). The  
87 p.Gly146Ala variant is common among individuals with a 46,XY DSD with a prevalence varying  
88 between 6.8 and 31% (15, 16). However, the minor allele frequency (MAF) (C allele) is also high in the  
89 overall control population (23.5%, gnomAD v3.1.2). Specifically, its MAF is increased approximately by  
90 1.3-3-fold in the East Asian and the African control populations, whereas it is only present in 1% of the  
91 European control population (gnomAD v3.1.2). Moreover, *in vitro* studies of transcriptional activity of  
92 the *NR5A1*/SF-1 p.Gly146Ala variant on several target promoters in various cell models found  
93 unaltered wild-type functionality (15, 17). In fact, some patients who carry severe, pathogenic  
94 *NR5A1*/SF-1 variants in compound heterozygous state with the p.Gly146Ala variant, do not  
95 phenotypically differ from individuals carrying the severe variant only (5, 16-22). The DSD causing

96 effect of the *NR5A1*/SF-1 p.Gly146Ala variant is therefore in doubt. However, given that oligogenic  
97 inheritance has been suggested for explaining the broad phenotype observed in individuals and  
98 families with *NR5A1*/SF-1 gene variants (23-29), the p.Gly146Ala variant might play a role as co-  
99 regulator or disease modifier of sexual development.

100 The aim of this study was therefore, to elucidate the role of the *NR5A1*/SF-1 p.Gly146Ala variant on  
101 sexual development. We studied 14 DSD patients carrying this variant by next generation sequencing  
102 (NGS). Specifically, we searched for other DSD-causing variants and their pathogenicity in order to  
103 assess the effect of the *NR5A1*/SF-1 p.Gly146Ala variant on the phenotype of its carriers.

104

## 105 **Patients and Methods**

### 106 **Patients and ethical approval**

107 We recruited 14 pediatric DSD individuals carrying the *NR5A1*/SF-1 p.Gly146Ala variant from a larger  
108 cohort of 125 DSD patients collected at the Biocruces Bizkaia Health Research Institute (Barakaldo,  
109 Spain). Clinical data were provided by the caring clinicians (Table 1 and S2 table). The study was  
110 approved by the ethics committee for clinical research of Euskadi (CEIC-E), Spain. Written informed  
111 consent was provided by the parents of the studied children.

112 Ten 46,XY DSD and four 46,XX DSD patients carrying the p.Gly146Ala variant in the *NR5A1*/SF-1 gene  
113 were analyzed using whole exome sequencing (WES) or a targeted gene panel comprised of 48 genes  
114 associated with sex determination, sex differentiation and hypogonadism (Supplementary table 1).

115

### 116 **Genetic analysis**

117 Genomic DNA from the patients was extracted from peripheral blood leukocytes using the MagPurix  
118 12S system (Zinexts Life Science Corp.). DNA purity and concentration were determined using a Qubit  
119 2.0 fluorometer (Thermo Fisher Scientific).

120 Initial characterization for the *NR5A1*/SF-1 p.Gly146Ala variant was done by a DSD specific panel.  
121 Additional NGS was performed by WES (Figure 1A). For WES, libraries were prepared using the Illumina  
122 DNA/RNA Prep Tagmentation PCR reagents (Illumina) and Illumina Exome Panel (CEX) according to  
123 the manufacturer's instructions. The resulting libraries were subjected to paired-end sequencing on a  
124 NovaSeq 6000 System (Illumina). Raw data were then converted to FastQ files for computational  
125 analysis, which included read alignment to the human genome reference sequence (GRCh38),  
126 duplicate marking, base quality score recalibration, indel realignment, and variant calling with an in-  
127 house bioinformatics pipeline using BWA-MEM (30) and GATK (31) software. Variants were annotated  
128 with WANNONAR (32) and filtration process of the exonic variants was performed using R software (R  
129 4.2.0). Variant filtration was performed following specific steps as given in Figure 1B.

130 These steps included the filtration of WES data by a DSD- and *NR5A1*-related gene list. These disease-  
131 tailored lists were updated from previously reported work (DSD-gene list, N=584; *NR5A1*-related gene  
132 list, N=628) (22, 32) (Figure 1 Step a). Then, we kept the resulting variants with all type of predicted  
133 consequences (e.g. nonsynonymous, frameshift deletion, stop/gain), but synonymous, and with a  
134 number of reads above or equal to 20 (33) (Figure 1 steps b and c). Next, we filtered to include variants  
135 with a  $MAF \leq 0.01$  according to gnomAD (v3.1.2) and depending on the origin and karyotype of the  
136 patient (Figure 1 step d). In step e, we confirmed the correct annotation, location of variants and  
137 zygosity by checking their alignment data in IGV (Integrative Genomics Viewer). Finally, we predicted  
138 the possible effect of the identified variant (see below) (Figure 1 step f). Variants were confirmed by  
139 visual examination using the IGV (Integrative Genomics Viewer) browser (34, 35).

140 For the targeted DSD-gene panel analysis, preparation of the libraries and sequencing have been  
141 described elsewhere (24). For variant filtration after panel analysis, same steps b to f were followed  
142 (Figure 1B).

143

#### 144 ***In silico* analyses and variant classification**

145 We predicted the possible effect of identified nonsynonymous genetic variants on the structure and  
146 function of the protein using Polyphen-2, (Polymorphism Phenotyping v2), Panther (Protein ANalysis  
147 THrough Evolutionary Relationships), SNPs and GO, CADD (Combined Annotation Dependent  
148 Depletion) and the calibrated scores given by VarSome (36) for Revel (Rare Exome Variant Ensemble  
149 Learner), SIFT (Scale-invariant feature transform), Provean (Protein Variation Effect Analyzer),  
150 Mutation taster and M-CAP (Mendelian Clinically Applicable Pathogenicity) (see Supplementary table  
151 3). Variants were classified for pathogenicity according to the standards and guidelines of the ACMG  
152 (6) using VarSome. We considered variants as candidates when classified as pathogenic, likely  
153 pathogenic or as VUS by the ACMG criteria or when classified as pathogenic or VUS by at least 7 out  
154 of 9 prediction programs. Previously reported clinical associations were searched in ClinVar and HGMD  
155 databases. In addition, the literature (e.g. PubMed) was searched for evidence of relationship with  
156 DSD, sex development and the specific clinical phenotype of each study subject. We explored the  
157 possible disease-causing variants' combinations using ORVAL (Oligogenic Resource for Variant  
158 AnaLysis) (37).

159

#### 160 **Results and Discussion**

161 In a random cohort of 125 subjects with a DSD, we identified the *NR5A1*/SF-1 p.Gly146Ala variant in  
162 14 individuals (11.2%). The prevalence in 46,XY DSD subjects was 10.1% (10/99), and was in line with  
163 previously reported prevalence in this population (15, 16). Prevalence was higher in 46,XX DSD (4/24,

164 16.7%). Of the 14 studied subjects, five were homozygous and nine heterozygous for the *NR5A1*/SF-1  
165 p.Gly146Ala variant. The phenotype of the individuals ranged from typical for karyotype to mild and  
166 severe atypical in 46,XY as well as opposite sex in both 46,XY and 46,XX (Figure 2). Patients were of  
167 African (8/14), Spanish (4/14) and Asian (2/14) origin. A summary of the clinical and biochemical  
168 characteristics of the patients is given in Table 1 and Supplementary table 2. An overview of the  
169 identified genes of our study subjects that likely play a role for the DSD phenotype in a concerted way  
170 is given in Figure 3. In this Figure 3 the identified variants are shown within the network of established  
171 genes of sex determination and differentiation.

172 NGS performed in DSD individuals harboring the p.Gly146Ala variant in *NR5A1*/SF-1 revealed several  
173 deleterious/candidate variants that potentially explain the phenotype of the patients. Overall, we  
174 identified either a known pathogenic DSD variant or one to four potentially deleterious/candidate  
175 variants in 10 out of the 14 DSD individuals analyzed. A detailed summary of identified variants in  
176 other DSD-related genes is shown in Table 2 (further details in Supplementary tables 3 and 4).

177 In three patients we detected variants in known DSD-causing genes with our targeted gene panel, e.g.  
178 *LHCGR*, *WT1*, and *AR*. In 11 patients WES was performed and variants were filtered by candidate gene  
179 lists (Figure 1). Overall, the NGS analysis identified 63 variants categorized as (likely) pathogenic or  
180 VUS in 57 different genes, however further review of evidence of correlation with DSD, sex  
181 development and phenotype of each patient with literature reduced this number to 20 potentially  
182 deleterious/candidate variants in 18 genes in 10 subjects. In nine 46,XY DSD individuals 1-4 variants  
183 were found in a total of 16 genes, while one 46,XX DSD person revealed two variants in two different  
184 genes (Table 2). All variants, identified either by gene panel or WES, but one (e.g. *LHCGR*), were  
185 detected in heterozygosis or hemizygososis. Details of the rejected variants are given in Supplementary  
186 table 4.

187 In **patient 1** two frameshift deletions in genes *FGFR3* (c.1633\_1634del; p.Cys545Hisfs\*17) and *INSR*  
188 (c.660\_661del; p.Pro220Hisfs\*4) and a stop-gain variant in *ADAMTS16* (c.1822\_1823del; p.His608\*)  
189 were found and predicted to be likely pathogenic by the ACMG criteria. *FGFR3* is essential for testicular  
190 development in humans (38), while *INSR* and *ADAMTS16* are needed in murine genitourinary  
191 development and testicular differentiation, respectively (39, 40). Variants in *ADAMTS16* have also  
192 been reported in heterozygosis in two 46,XY females with complete gonadal dysgenesis and a 46,XY  
193 DSD patient with ambiguous genitalia (41). Testing for a digenic combination network with ORVAL  
194 showed no variant interaction between *ADAMTS16* and *FGFR3*.

195 We detected four heterozygous missense variants in four genes in **patient 3**. These were *GLI2*  
196 (c.3528G>T; p.Gln1176His), *CDH7* (c.1623C>A; p.His541Gln), *MYO7A* (c.2882G>A; p.Gly961Asp) and  
197 *VDR* (c.176C>T; p.Thr59Ile). The variant in *GLI2* (c.3528G>T; p.Gln1176His) was rated as pathogenic by

198 most of the *in silico* prediction tools and variants in additional genes were rated as VUS when analyzing  
199 according to pathogenicity guidelines. Variants in *GLI2* have been described in syndromic DSD patients  
200 together with short stature, primary hypogonadism, heart and craniofacial anomalies and 46,XY  
201 gonadal dysgenesis (42), as well as in 46,XY non-syndromic DSD manifesting with female external  
202 genitalia or with ambiguous genitalia (23, 43, 44). Variants in *CHD7* have been previously associated  
203 with a broad range of 46,XY DSD phenotypes, including males with hypospadias or micropenis and  
204 individuals with female external genitalia (27, 45). *MYO7A* is overexpressed in male supporting cells  
205 during gonadal development (46) and has been shown to be a SRY and SOX9 target gene (47), but, in  
206 DSD individuals it has been identified only in combination with *MAMLD1* (44, 48). Finally, *VDR* plays a  
207 dominant role in male fertility as *Vdr*<sup>-/-</sup> mice show abnormal gonads in both sexes and variable  
208 reproductive phenotypes such as reduced sperm count (49). In humans, two polymorphisms in *VDR*  
209 were associated with female idiopathic infertility only (50). Fertility of patient 3 has not been assessed  
210 yet, and we cannot exclude a role of the *VDR* variant in his DSD phenotype. Network analysis by ORVAL  
211 predicts a pathogenic gene network between *CHD7*, *MYO7A* and *GLI2* (Supplementary figure 1A).  
212 A heterozygous missense c.182C>A; p.Pro61Gln variant in Neuropilin 1 (*NRP1*) gene was found in  
213 **patient 6**. *NRP1* interacts with Sema3A which is essential for the development of the GnRH neuron  
214 system (51). Loss of Sema3a (Semaphorin 3A) signaling in mice results in reduced gonadal size and  
215 recapitulates the features of Kallmann syndrome (52). In humans, variants in *NRP1* have been  
216 identified in a 46,XY DSD subject with female external genitalia (45) and a 46,XY male presenting with  
217 penoscrotal hypospadias, in whom other genetic variants were identified, among them a variant in  
218 *MAMLD1*, a known DSD-related gene (48).  
219 In 46,XY **patient 8** with a phenotype of opposite sex a homozygous, inactivating variant in *LHCGR*  
220 (c.757T>C; p.Ser253Pro) was found. This variant has been previously reported to severely reduce the  
221 signal transduction activity of the LH receptor and therefore leads to the complete form of Leydig cell  
222 hypoplasia (LCH) as seen in patient 8 (53).  
223 A novel, likely pathogenic p.Met255Lys (c.764T>A) missense variant in exon 2 of *WT1* was found in  
224 **patient 9**, who had precocious puberty and presented with a pituitary adenoma and hearing loss. *WT1*  
225 is associated with 46,XY gonadal dysgenesis in syndromes including Denys-Drash or Frasier (54), but  
226 more recently *WT1* variants have also been detected in individuals with isolated DSD, such as  
227 ambiguous genitalia (45, 55, 56) or gonadal dysgenesis. *WT1* acts as a transcriptional repressor or  
228 activator on many target genes, such as *LHB* (Luteinizing Hormone Subunit Beta), which encodes the  
229 beta subunit of LH (luteinizing hormone), responsible for testosterone production in males during  
230 puberty. Variants of *WT1* may therefore affect the transcription of LH $\beta$  and thereby lead to altered  
231 puberty timing as observed in patient 9. In fact, in mouse cell models, *WT1* regulates *LHB* transcription

232 and two splice variants (-KTS/+KTS) were already shown to have positive and negative roles in this  
233 regulation (57).

234 A missense variant in *COL27A1* (c.3715C>T; p.Arg1239Trp) and a frameshift insertion in *TYRO3*  
235 (c.666\_667insCACTGCCTGCAGCCCCCTTCAACATCACCC; p.Ala223HisfsTer21) were found in **patient 10**.  
236 Both variants were categorized as VUS and were detected in heterozygosis. In mice, *Col27a1* is highly  
237 expressed in XY somatic supporter cells compared to XX during the earliest stages of gonad  
238 development (58). *Col27a1* has been identified as a SRY target gene in the embryonic mouse gonads  
239 at E11.5 by ChIP-Chip experiments (47). Similarly, *Tyro3* is overexpressed in male somatic cells (59),  
240 and is regulated by SOX9 (47). Protein truncating variants of *TYRO3* were found in individuals with  
241 idiopathic hypogonadotropic hypogonadism establishing a role of this gene in reproductive  
242 development (60). Taken together, the data suggest that both *COL27A1* and *TYRO3* genes are part of  
243 the genetic network underlying the early stages of mammalian fetal gonadal development, and thus  
244 genetic changes are likely causing the ovotesticular DSD phenotype in patient 10. However, a gene  
245 interaction between *COL27A1* and *TYRO3* was not predicted by ORVAL.

246 In 46,XY **patient 11** with a distal hypospadias, one missense variant in the *SOX8* (c.676A>C;  
247 p.Thr226Pro) gene was detected. It was identified in heterozygosis and was classified as VUS. *SOX8* is  
248 involved in early testis determination (61). *SOX8* gene variants are associated with a range of  
249 phenotypes including 46,XY DSD and human reproductive anomalies in males and females (62). Single-  
250 nucleotide variants (SNV) associated with 46,XY gonadal dysgenesis are mostly located in the HMG-  
251 box of *SOX8* (43), while those reported in infertile patients flank the HMG-box or localize to one of the  
252 transactivation domains (TA) (62). However, more recently, a missense variant in the TA2 region of  
253 *SOX8* was identified in a 46,XY patient with gonadal dysgenesis (43). The novel c.676A>C; p.Thr226Pro  
254 variant is located in the first TA of the protein. *In vitro* studies have shown impaired cellular localization  
255 in some mutant proteins located in this functional domain of *SOX8*. Therefore, this missense variant  
256 likely explains the genital phenotype observed in patient 11. Biochemical assessment (age range 11-  
257 15) of the HPG axis was normal and pubertal development was ongoing (Tanner 3-4).

258 Four heterozygous VUS or likely pathogenic variants were identified in **patient 12** with a severe 46,XY  
259 DSD phenotype. These were *POR* (c.1679C>T; p.Thr560Met), *PKD1* (c.2624C>T; p.Pro875Leu), *SRCAP*  
260 (c.7142G>A; p.Arg2381His) and *SOX9* (c.710dup; p.Pro238Thrfs\*14). The involvement of *POR* and  
261 *SOX9* in sexual development is well known and several sequence variants have been described in 46,XY  
262 DSD patients (27, 47, 63). *Pkd1* is critical for epididymal epithelium development and for maintaining  
263 mice male reproductive tract (64). *PKD1* variants have not been related to DSD yet, but they cause  
264 autosomal dominant polycystic kidney disease (ADPKD), which involves reproductive tract  
265 abnormalities and infertility in males (65). Therefore, a role of *PKD1* variants in DSD seems possible.



266 Likewise, the role of *SRCAP* in sex differentiation and development is unknown. However, this is the  
267 second 46,XY DSD patient in whom a gene variant is identified (42). According to ORVAL analysis,  
268 oligogenic pathogenicity is predicted by combination of variants in a gene network including *POR*,  
269 *PKD1* and *SRCAP* (Supplementary figure 1B).

270 In **patient 13**, we identified an *AR* variant (c.2323C>T; p.Arg775Cys) previously reported in a patient  
271 with Complete Androgen Insensitivity Syndrome (CAIS) (66). Because the patient presented with a  
272 typical CAIS phenotype, it seems plausible that this hemizygous *AR* variant is fully responsible for the  
273 DSD.

274 **Patient 14**, with a severe 46,XY phenotype, harbored two heterozygous missense variants in *MYO7A*  
275 and *SOX8* genes. Both were categorized as VUS by the ACMG. As in patient 11, the *SOX8* variant  
276 (c.694A>C; p.Lys232Gln) was also located in the TA1 domain of the protein. However, the phenotype  
277 of patient 14 was more severe, either caused by the *SOX8* variant alone or due to the digenic effect  
278 together with *MYO7A*. Importantly, the combination of variants in *SOX8* and *MYO7A* is predicted as  
279 disease-causing by ORVAL (Supplementary figure 1C). The combination of variants in *MYO7A* and *SOX8*  
280 in DSD was reported previously (44, 48), and suggests that the broad phenotype observed in DSD  
281 individuals might be explained by oligogenic origin (67).

282

283 In four patients carrying the heterozygous p.Gly146Ala *NR5A1* variant, the WES and specific data  
284 analysis revealed no other candidate genes explaining their DSD phenotype. Of these patients 2, 4 and  
285 5 had a 46,XX karyotype and an opposite genital phenotype, and were assigned as males at birth,  
286 whereas patient 7 presented with a severe 46,XY DSD. None had other organ anomalies. Although  
287 NGS has facilitated the identification of the underlying genetic defects of DSD, about 50% of  
288 individuals with a 46,XY DSD remain without a molecular diagnosis with currently used methods (27).  
289 We used WES in our study, while other genetic studies also search for variants in noncoding, regulatory  
290 or intronic regions by whole genome sequencing (WGS). But even when using WGS, a considerable  
291 number of patients are reportedly unsolved (68). Thus, other factors such as environmental factors or  
292 epigenetic regulators have been suggested playing a role (68, 69). In addition, oligogenic or even  
293 polygenic inheritance might be considered for explaining the broad phenotypes seen in some  
294 individuals with a DSD (23-29, 48, 67, 70-73). In early days of genetic workup of DSD, patients were  
295 studied by candidate Sanger sequencing. In 46,XY DSD subjects typical candidates were the *AR*,  
296 *SRD5A2* and *NR5A1/SF-1*; and once a genetic variant was found, additional genes were not tested.  
297 Thus, some DSD patients that have been tested by the candidate approach may not have a correct  
298 diagnosis and need to be retested by NGS.

299 In conclusion, NGS genetic analysis of DSD individuals carrying the p.Gly146Ala variant of the  
300 *NR5A1/SF-1* gene revealed variants in other genes (likely) explaining their phenotype. These gene  
301 variants were either found in established DSD genes, were previously described or novel, and were  
302 (likely) disease-causing either in a monogenic or in a suggested oligogenic fashion. Although we were  
303 not able to find causal genetic variants in four out of 14 DSD individuals carrying the *NR5A1/SF-1*  
304 p.Gly146Ala, our study supports the claim that this *NR5A1/SF-1* variant is a benign polymorphism that  
305 does not play a role in the pathogenesis of DSD. Therefore, we strongly recommend reanalyzing DSD  
306 patients of whom phenotype has been thought to be explained by this variant in order to find the real  
307 underlying genetic cause.

308

### 309 **Acknowledgement**

310 The authors thank the patients and their families for participating in our research.

311

### 312 **Competing interests**

313 The authors have declared that no competing interests exist.

314

### 315 **Funding**

316 This work has been supported by the University of the Basque Country (UPV-EHU) (Spain) (IT1739-22)  
317 and by the Swiss National Science Foundation (320030-197725). IM is supported by a Postdoctoral  
318 Fellowship Grant from the Education Department of Basque Government (Spain). JA is supported by  
319 ASONMEC (Asociacion de Oncologia Medica del Hospital de Cruces) (Spain).

320

### 321 **Supporting information**

322 S1 Table. Genes included in the customized DSD panel and their suggested role in DSD.

323 S2 Table. Complete description of the phenotype and biochemical data of the DSD patients harbouring  
324 the *NR5A1/SF-1* p.Gly146Ala variant.

325 S3 Table 3. Gene variant characterization: allele frequency and disease prediction by ACMG  
326 classification and by different in silico programs

327 aSpecific allele frequency for the origin and karyotype of the patient. bCADD phred score >20 indicates  
328 that the variant is predicted to be the 1% most deleterious substitution that you can do to the human  
329 genome.

330 S4 Table. List of rejected variants identified in the DSD patients harbouring the *NR5A1/SF-1*  
331 p.Gly146Ala variant. Variants were discarded after filtering due to weak relation to DSD, zygosity or  
332 absence of correspondence to the phenotype.

333 S1 Figure. Potential oligogenic interaction networks of DSD- and NR5A1-related genes identified in  
334 specific DSD individuals harbouring the NR5A1/SF-1 p.Gly146Ala variant. Networks were identified for  
335 patients 3, 12 and 14 respectively. To search for potential oligogenic disease networks, the Oligogenic  
336 Resource for Variant AnaLysis (ORVAL, <https://orval.ibsquare.be/>) was used. Nodes represent genes  
337 and edges connect two genes only, if between them there is at least one candidate disease-causing  
338 variant combination predicted by VarCoPP. The colour of the edge represents the pathogenicity score  
339 for that pair of genes. This score is represented in a colour range from brown (higher pathogenicity  
340 score) to yellow (lower pathogenicity score).  
341

## 342 References

- 343 1. Eggers S, Ohnesorg T, Sinclair A. Genetic regulation of mammalian gonad development.  
344 *Nature reviews Endocrinology*. 2014;10(11):673-83.
- 345 2. Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B, et al. Gonadal  
346 determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic  
347 factor-1, in a dose-dependent manner. *The Journal of clinical endocrinology and metabolism*.  
348 2002;87(4):1829-33.
- 349 3. Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson JL. A mutation in the gene encoding  
350 steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. *Nature genetics*.  
351 1999;22(2):125-6.
- 352 4. Fabbri-Scallet H, de Sousa LM, Maciel-Guerra AT, Guerra-Júnior G, de Mello MP. Mutation  
353 update for the NR5A1 gene involved in DSD and infertility. *Hum Mutat*. 2020;41(1):58-68.
- 354 5. Domenice S, Machado AZ, Ferreira FM, Ferraz-de-Souza B, Lerario AM, Lin L, et al. Wide  
355 spectrum of NR5A1-related phenotypes in 46,XY and 46,XX individuals. *Birth defects research Part C*,  
356 *Embryo today : reviews*. 2016;108(4):309-20.
- 357 6. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for  
358 the interpretation of sequence variants: a joint consensus recommendation of the American College  
359 of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in  
360 medicine : official journal of the American College of Medical Genetics*. 2015;17(5):405-24.
- 361 7. WuQiang F, Yanase T, Wei L, Oba K, Nomura M, Okabe T, et al. Functional characterization of  
362 a new human Ad4BP/SF-1 variation, G146A. *Biochem Biophys Res Commun*. 2003;311(4):987-94.
- 363 8. Wada Y, Okada M, Fukami M, Sasagawa I, Ogata T. Association of cryptorchidism with  
364 Gly146Ala polymorphism in the gene for steroidogenic factor-1. *Fertility and sterility*.  
365 2006;85(3):787-90.
- 366 9. Paris F, De Ferran K, Bhangoo A, Ten S, Lahlou N, Audran F, et al. Isolated 'idiopathic'  
367 micropenis: hidden genetic defects? *Int J Androl*. 2011;34(6 Pt 2):e518-25.
- 368 10. Wada Y, Okada M, Hasegawa T, Ogata T. Association of severe micropenis with Gly146Ala  
369 polymorphism in the gene for steroidogenic factor-1. *Endocrine journal*. 2005;52(4):445-8.
- 370 11. Bashamboo A, Ferraz-de-Souza B, Lourenço D, Lin L, Sebire NJ, Montjean D, et al. Human  
371 male infertility associated with mutations in NR5A1 encoding steroidogenic factor 1. *Am J Hum  
372 Genet*. 2010;87(4):505-12.
- 373 12. Röpke A, Tewes AC, Gromoll J, Kliesch S, Wieacker P, Tüttelmann F. Comprehensive  
374 sequence analysis of the NR5A1 gene encoding steroidogenic factor 1 in a large group of infertile  
375 males. *European journal of human genetics : EJHG*. 2013;21(9):1012-5.
- 376 13. Philibert P, Paris F, Lakhali B, Audran F, Gaspari L, Saâd A, et al. NR5A1 (SF-1) gene variants in  
377 a group of 26 young women with XX primary ovarian insufficiency. *Fertility and sterility*.  
378 2013;99(2):484-9.
- 379 14. Liu W, Liu M, Fan W, Nawata H, Yanase T. The Gly146Ala variation in human SF-1 gene: its  
380 association with insulin resistance and type 2 diabetes in Chinese. *Diabetes Res Clin Pract*.  
381 2006;73(3):322-8.
- 382 15. Camats N, Pandey AV, Fernández-Cancio M, Andaluz P, Janner M, Torán N, et al. Ten novel  
383 mutations in the NR5A1 gene cause disordered sex development in 46,XY and ovarian insufficiency  
384 in 46,XX individuals. *The Journal of clinical endocrinology and metabolism*. 2012;97(7):E1294-306.
- 385 16. Tantawy S, Mazen I, Soliman H, Anwar G, Atef A, El-Gammal M, et al. Analysis of the gene  
386 coding for steroidogenic factor 1 (SF1, NR5A1) in a cohort of 50 Egyptian patients with 46,XY  
387 disorders of sex development. *European journal of endocrinology*. 2014;170(5):759-67.
- 388 17. Reuter AL, Goji K, Bingham NC, Matsuo M, Parker KL. A novel mutation in the accessory  
389 DNA-binding domain of human steroidogenic factor 1 causes XY gonadal dysgenesis without adrenal  
390 insufficiency. *European journal of endocrinology*. 2007;157(2):233-8.

- 391 18. Köhler B, Lin L, Ferraz-de-Souza B, Wieacker P, Heidemann P, Schröder V, et al. Five novel  
392 mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY patients with severe underandrogenization  
393 but without adrenal insufficiency. *Hum Mutat.* 2008;29(1):59-64.
- 394 19. Hasegawa T, Fukami M, Sato N, Katsumata N, Sasaki G, Fukutani K, et al. Testicular  
395 dysgenesis without adrenal insufficiency in a 46,XY patient with a heterozygous inactive mutation of  
396 steroidogenic factor-1. *The Journal of clinical endocrinology and metabolism.* 2004;89(12):5930-5.
- 397 20. Bertelloni S, Dati E, Baldinotti F, Toschi B, Marrocco G, Sessa MR, et al. NR5A1 gene  
398 mutations: clinical, endocrine and genetic features in two girls with 46,XY disorder of sex  
399 development. *Hormone research in paediatrics.* 2014;81(2):104-8.
- 400 21. Woo KH, Cheon B, Kim JH, Cho J, Kim GH, Yoo HW, et al. Novel Heterozygous Mutations of  
401 NR5A1 and Their Functional Characteristics in Patients with 46,XY Disorders of Sex Development  
402 without Adrenal Insufficiency. *Hormone research in paediatrics.* 2015;84(2):116-23.
- 403 22. Adamovic T, Chen Y, Thai HT, Zhang X, Markljung E, Zhao S, et al. The p.G146A and p.P125P  
404 polymorphisms in the steroidogenic factor-1 (SF-1) gene do not affect the risk for hypospadias in  
405 Caucasians. *Sexual development : genetics, molecular biology, evolution, endocrinology,*  
406 *embryology, and pathology of sex determination and differentiation.* 2012;6(6):292-7.
- 407 23. Camats N, Fernández-Cancio M, Audí L, Schaller A, Flück CE. Broad phenotypes in  
408 heterozygous NR5A1 46,XY patients with a disorder of sex development: an oligogenic origin?  
409 *European journal of human genetics : EJHG.* 2018;26(9):1329-38.
- 410 24. Martínez de LaPiscina I, Mahmoud RA, Sauter KS, Esteva I, Alonso M, Costa I, et al. Variants  
411 of STAR, AMH and ZFPM2/FOG2 May Contribute towards the Broad Phenotype Observed in 46,XY  
412 DSD Patients with Heterozygous Variants of NR5A1. *International journal of molecular sciences.*  
413 2020;21(22).
- 414 25. Mazen I, Abdel-Hamid M, Mekkawy M, Bignon-Topalovic J, Boudjenah R, El Gammal M, et al.  
415 Identification of NR5A1 Mutations and Possible Digenic Inheritance in 46,XY Gonadal Dysgenesis.  
416 *Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and*  
417 *pathology of sex determination and differentiation.* 2016;10(3):147-51.
- 418 26. Werner R, Mönig I, Lünstedt R, Wünsch L, Thorns C, Reiz B, et al. New NR5A1 mutations and  
419 phenotypic variations of gonadal dysgenesis. *PloS one.* 2017;12(5):e0176720.
- 420 27. Eggers S, Sadedin S, van den Bergen JA, Robevska G, Ohnesorg T, Hewitt J, et al. Disorders of  
421 sex development: insights from targeted gene sequencing of a large international patient cohort.  
422 *Genome biology.* 2016;17(1):243.
- 423 28. Robevska G, van den Bergen JA, Ohnesorg T, Eggers S, Hanna C, Hersmus R, et al. Functional  
424 characterization of novel NR5A1 variants reveals multiple complex roles in disorders of sex  
425 development. *Hum Mutat.* 2018;39(1):124-39.
- 426 29. Wang H, Zhang L, Wang N, Zhu H, Han B, Sun F, et al. Next-generation sequencing reveals  
427 genetic landscape in 46, XY disorders of sexual development patients with variable phenotypes.  
428 *Human genetics.* 2018;137(3):265-77.
- 429 30. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform.  
430 *Bioinformatics.* 2010;26(5):589-95.
- 431 31. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al.  
432 From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices  
433 pipeline. *Curr Protoc Bioinformatics.* 2013;43(1110):11.0.1-.0.33.
- 434 32. Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and  
435 wANNOVAR. *Nat Protoc.* 2015;10(10):1556-66.
- 436 33. Meynert AM, Ansari M, FitzPatrick DR, Taylor MS. Variant detection sensitivity and biases in  
437 whole genome and exome sequencing. *BMC Bioinformatics.* 2014;15(1):247.
- 438 34. Artech-López A, Ávila-Fernández A, Romero R, Riveiro-Álvarez R, López-Martínez MA,  
439 Giménez-Pardo A, et al. Sanger sequencing is no longer always necessary based on a single-center  
440 validation of 1109 NGS variants in 825 clinical exomes. *Scientific reports.* 2021;11(1):5697.

- 441 35. De Cario R, Kura A, Suraci S, Magi A, Volta A, Marcucci R, et al. Sanger Validation of High-  
442 Throughput Sequencing in Genetic Diagnosis: Still the Best Practice? *Frontiers in genetics*.  
443 2020;11:592588.
- 444 36. Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, et al. VarSome:  
445 the human genomic variant search engine. *Bioinformatics*. 2019;35(11):1978-80.
- 446 37. Renaux A, Papadimitriou S, Versbraegen N, Nachtegaal C, Boutry S, Nowé A, et al. ORVAL: a  
447 novel platform for the prediction and exploration of disease-causing oligogenic variant  
448 combinations. *Nucleic Acids Res*. 2019;47(W1):W93-w8.
- 449 38. Ewen KA, Olesen IA, Winge SB, Nielsen AR, Nielsen JE, Graem N, et al. Expression of FGFR3  
450 during human testis development and in germ cell-derived tumours of young adults. *Int J Dev Biol*.  
451 2013;57(2-4):141-51.
- 452 39. Pitetti JL, Calvel P, Zimmermann C, Conne B, Papaioannou MD, Aubry F, et al. An essential  
453 role for insulin and IGF1 receptors in regulating sertoli cell proliferation, testis size, and FSH action in  
454 mice. *Molecular endocrinology (Baltimore, Md)*. 2013;27(5):814-27.
- 455 40. Jacobi CL, Rudigier LJ, Scholz H, Kirschner KM. Transcriptional regulation by the Wilms tumor  
456 protein, Wt1, suggests a role of the metalloproteinase Adamts16 in murine genitourinary  
457 development. *J Biol Chem*. 2013;288(26):18811-24.
- 458 41. Barseghyan H, Symon A, Zadikyan M, Almalvez M, Segura EE, Eskin A, et al. Identification of  
459 novel candidate genes for 46,XY disorders of sex development (DSD) using a C57BL/6J-Y (POS) mouse  
460 model. *Biol Sex Differ*. 2018;9(1):8.
- 461 42. Globa E, Zelinska N, Shcherbak Y, Bignon-Topalovic J, Bashamboo A, McElreavey K. Disorders  
462 of Sex Development in a Large Ukrainian Cohort: Clinical Diversity and Genetic Findings. *Frontiers in*  
463 *endocrinology*. 2022;13:810782.
- 464 43. Zidoune H, Ladjouze A, Chellat-Rezgoune D, Boukri A, Dib SA, Nouri N, et al. Novel Genomic  
465 Variants, Atypical Phenotypes and Evidence of a Digenic/Oligogenic Contribution to  
466 Disorders/Differences of Sex Development in a Large North African Cohort. *Frontiers in genetics*.  
467 2022;13:900574.
- 468 44. Li L, Gao F, Fan L, Su C, Liang X, Gong C. Disorders of Sex Development in Individuals  
469 Harbouring MAMLD1 Variants: WES and Interactome Evidence of Oligogenic Inheritance. *Frontiers in*  
470 *endocrinology*. 2020;11:582516.
- 471 45. Baxter RM, Arboleda VA, Lee H, Barseghyan H, Adam MP, Fechner PY, et al. Exome  
472 sequencing for the diagnosis of 46,XY disorders of sex development. *The Journal of clinical*  
473 *endocrinology and metabolism*. 2015;100(2):E333-44.
- 474 46. Jameson SA, Lin YT, Capel B. Testis development requires the repression of Wnt4 by Fgf  
475 signaling. *Developmental biology*. 2012;370(1):24-32.
- 476 47. Li Y, Zheng M, Lau YF. The sex-determining factors SRY and SOX9 regulate similar target  
477 genes and promote testis cord formation during testicular differentiation. *Cell Rep*. 2014;8(3):723-  
478 33.
- 479 48. Flück CE, Audí L, Fernández-Cancio M, Sauter KS, Martínez de LaPiscina I, Castaño L, et al.  
480 Broad Phenotypes of Disorders/Differences of Sex Development in MAMLD1 Patients Through  
481 Oligogenic Disease. *Frontiers in genetics*. 2019;10:746.
- 482 49. Kinuta K, Tanaka H, Moriwake T, Aya K, Kato S, Seino Y. Vitamin D is an important factor in  
483 estrogen biosynthesis of both female and male gonads. *Endocrinology*. 2000;141(4):1317-24.
- 484 50. Djurovic J, Stamenkovic G, Todorovic J, Aleksic N, Stojkovic O. Polymorphisms and  
485 haplotypes in VDR gene are associated with female idiopathic infertility. *Hum Fertil (Camb)*.  
486 2020;23(2):101-10.
- 487 51. Cariboni A, Hickok J, Rakic S, Andrews W, Maggi R, Tischkau S, et al. Neuropilins and their  
488 ligands are important in the migration of gonadotropin-releasing hormone neurons. *J Neurosci*.  
489 2007;27(9):2387-95.
- 490 52. Cariboni A, Davidson K, Rakic S, Maggi R, Parnavelas JG, Ruhrberg C. Defective gonadotropin-  
491 releasing hormone neuron migration in mice lacking SEMA3A signalling through NRP1 and NRP2:

- 492 implications for the aetiology of hypogonadotropic hypogonadism. *Human molecular genetics*.  
493 2011;20(2):336-44.
- 494 53. Qiao J, Han B. Diseases caused by mutations in luteinizing hormone/chorionic gonadotropin  
495 receptor. *Prog Mol Biol Transl Sci*. 2019;161:69-89.
- 496 54. McTaggart SJ, Algar E, Chow CW, Powell HR, Jones CL. Clinical spectrum of Denys-Drash and  
497 Frasier syndrome. *Pediatr Nephrol*. 2001;16(4):335-9.
- 498 55. Dabrowski E, Armstrong AE, Leeth E, Johnson E, Cheng E, Gosiengfiao Y, et al. Proximal  
499 Hypospadias and a Novel WT1 Variant: When Should Genetic Testing Be Considered? *Pediatrics*.  
500 2018;141(Suppl 5):S491-s5.
- 501 56. Wang Y, Li Q, Xu J, Liu Q, Wang W, Lin Y, et al. Mutation analysis of five candidate genes in  
502 Chinese patients with hypospadias. *European journal of human genetics : EJHG*. 2004;12(9):706-12.
- 503 57. Bagchi D, Andrade J, Shupnik MA. A new role for wilms tumor protein 1: differential activities  
504 of + KTS and -KTS variants to regulate LH $\beta$  transcription. *PloS one*. 2015;10(1):e0116825.
- 505 58. Bouma GJ, Hudson QJ, Washburn LL, Eicher EM. New Candidate Genes Identified for  
506 Controlling Mouse Gonadal Sex Determination and the Early Stages of Granulosa and Sertoli Cell  
507 Differentiation1. *Biology of Reproduction*. 2010;82(2):380-9.
- 508 59. Beverdam A, Koopman P. Expression profiling of purified mouse gonadal somatic cells during  
509 the critical time window of sex determination reveals novel candidate genes for human sexual  
510 dysgenesis syndromes. *Human molecular genetics*. 2006;15(3):417-31.
- 511 60. Guo MH, Plummer L, Chan YM, Hirschhorn JN, Lippincott MF. Burden Testing of Rare  
512 Variants Identified through Exome Sequencing via Publicly Available Control Data. *Am J Hum Genet*.  
513 2018;103(4):522-34.
- 514 61. Eggers S, Sinclair A. Mammalian sex determination—insights from humans and mice.  
515 *Chromosome research : an international journal on the molecular, supramolecular and evolutionary*  
516 *aspects of chromosome biology*. 2012;20(1):215-38.
- 517 62. Portnoi MF, Dumargne MC, Rojo S, Witchel SF, Duncan AJ, Eozenou C, et al. Mutations  
518 involving the SRY-related gene SOX8 are associated with a spectrum of human reproductive  
519 anomalies. *Human molecular genetics*. 2018;27(7):1228-40.
- 520 63. Miller WL, Huang N, Pandey AV, Flück CE, Agrawal V. P450 oxidoreductase deficiency: a new  
521 disorder of steroidogenesis. *Ann N Y Acad Sci*. 2005;1061:100-8.
- 522 64. Nie X, Arend LJ. Pkd1 is required for male reproductive tract development. *Mech Dev*.  
523 2013;130(11-12):567-76.
- 524 65. Liu B, Chen SC, Yang YM, Yan K, Qian YQ, Zhang JY, et al. Identification of novel PKD1 and  
525 PKD2 mutations in a Chinese population with autosomal dominant polycystic kidney disease.  
526 *Scientific reports*. 2015;5:17468.
- 527 66. Brown TR, Lubahn DB, Wilson EM, French FS, Migeon CJ, Corden JL. Functional  
528 characterization of naturally occurring mutant androgen receptors from subjects with complete  
529 androgen insensitivity. *Molecular endocrinology (Baltimore, Md)*. 1990;4(12):1759-72.
- 530 67. Camats N, Flück CE, Audí L. Oligogenic Origin of Differences of Sex Development in Humans.  
531 *International journal of molecular sciences*. 2020;21(5).
- 532 68. Délot EC, Vilain E. Towards improved genetic diagnosis of human differences of sex  
533 development. *Nature reviews Genetics*. 2021;22(9):588-602.
- 534 69. Bouty A, Ayers KL, Pask A, Heloury Y, Sinclair AH. The Genetic and Environmental Factors  
535 Underlying Hypospadias. *Sexual development : genetics, molecular biology, evolution,*  
536 *endocrinology, embryology, and pathology of sex determination and differentiation*. 2015;9(5):239-  
537 59.
- 538 70. Martinez de LaPiscina I, Flück CE. Genetics of human sexual development and related  
539 disorders. *Current opinion in pediatrics*. 2021;33(6):556-63.
- 540 71. Martinez de LaPiscina I, de Mingo C, Riedl S, Rodriguez A, Pandey AV, Fernández-Cancio M,  
541 et al. GATA4 Variants in Individuals With a 46,XY Disorder of Sex Development (DSD) May or May

542 Not Be Associated With Cardiac Defects Depending on Second Hits in Other DSD Genes. *Frontiers in*  
543 *endocrinology*. 2018;9:142.

544 72. Zhang W, Shi J, Zhang C, Jiang X, Wang J, Wang W, et al. Identification of gene variants in 130  
545 Han Chinese patients with hypospadias by targeted next-generation sequencing. *Molecular genetics*  
546 *& genomic medicine*. 2019;7(8):e827.

547 73. Kolesinska Z, Acierno J, Jr., Ahmed SF, Xu C, Kapczuk K, Skorczyk-Werner A, et al. Integrating  
548 clinical and genetic approaches in the diagnosis of 46,XY disorders of sex development. *Endocrine*  
549 *connections*. 2018;7(12):1480-90.

550 74. 60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). *Hormone*  
551 *research in paediatrics*. 2022;95(suppl 2)(2):1-616.

552 75. Gentilin B, Forzano F, Bedeschi MF, Rizzuti T, Faravelli F, Izzi C, et al. Phenotype of five cases  
553 of prenatally diagnosed campomelic dysplasia harboring novel mutations of the SOX9 gene.

554 *Ultrasound Obstet Gynecol*. 2010;36(3):315-23.

555



Table 1. Phenotype of the DSD patients harbouring the *NR5A1*/SF-1 p.Gly146Ala variant. Further details including biochemical data are given in Supplementary table 2.

Patient/Origin <sup>a</sup>	Karyotype/Sex assignment <sup>b</sup>	Zygoty <sup>c</sup>	Age range at diagnosis	External genital phenotype <sup>d</sup>	Internal phenotype	Gonadal/reproductive function	Other organ anomalies
1 <sup>1</sup>	46,XY/M	Het	0-5y	Mild	Laparoscopy: absence of female organs and gonadal tissue. Histology: undifferentiated tissue.	0-5y, abnormal (no T response to hCG)	No
2 <sup>2</sup>	46,XX/M	Het	6-10y	Opposite sex	US: no Müllerian ducts. Histology: infantile ovary with follicular cysts, fallopian tube, atrophic uterus, mesonephric remnant.	hCG test with hyperandrogenic reaction for typical male	No
3 <sup>2</sup>	46,XY/M	Het	6-10y	Severe	US: inguinal testes (right 0.5cc; left 0.6cc).	6-10y, normal hCG test	No
4 <sup>2</sup>	46,XX/M	Hom	6-10y	Opposite sex	Laparoscopy: bilateral gonads in inguinal canal and iliac area, atrophic uterus. No Müllerian ducts. Histology: bilateral ovotestes.	hCG test with hyperandrogenic reaction for typical male	No
5 <sup>2</sup>	46,XX/M	Hom	0-5y	Opposite sex	US: inguinal bilateral gonads (1ml), no Müllerian ducts. Histology: ovarian tissue (left), testicular and ovarian tissue (right).	hCG test with hyperandrogenic reaction for typical male	No
6 <sup>2</sup>	46,XY/M	Het	0-5y	Mild	MRI: absence of uterus and ovaries.	0-5y, normal baseline and hCG test	Anal agenesis, iron deficiency
7 <sup>2</sup>	46,XY/M	Hom	6-10y	Severe	US: scrotal right testis (15x9mm), inguinal left testis (13x6mm).	6-10y, normal baseline and hCG test	No
8 <sup>2</sup>	46,XY/F	Het	6-10y	Opposite sex	US: vaginal opening, no uterus. Histology: normal testis tissue at age ranges 6-10y and 21-25y.	31-35y, abnormal (high gonadotropins and low T)	No
9 <sup>3</sup>	46,XY/M	Hom	6-10y	Typical	ND	6-10y, high T at baseline	Pituitary adenoma, hearing loss
10 <sup>2</sup>	46,XX/M	Hom	0-5y	Opposite sex	US: prepubertal uterus. Histology: ovarian tissue (left), testicular and ovarian tissue (right).	Prepubertal	No
11 <sup>1</sup>	46,XY/M	Het	0-5y	Mild	US: normal size intrascrotal testes.	11-15y, normal (normal T and gonadotropins)	No
12 <sup>3</sup>	46,XY/M	Het	0-5y	Severe	ND	ND	Left renal agenesis, lipomeningocele
13 <sup>1</sup>	46,XY/F	Het	11-15y	Opposite sex	Infantile uterus and ovaries by ultrasound.	ND	Abdominal obesity
14 <sup>1</sup>	46,XY/M	Het	0-5y	Severe	US: normal uterus, absence of gonads.	Abnormal (high gonadotropins and normal T)	No

F, female; hCG, human chorionic gonadotropin; M, male; MRI, magnetic resonance imaging; ND, not determined; T, testosterone; US, ultrasound; y, years. <sup>a</sup>Origin of the patients: <sup>1</sup>Spanish; <sup>2</sup>African; <sup>3</sup>Asian. <sup>b</sup>None of the patients was sex re-assigned. <sup>c</sup>Zygoty of the *NR5A1*/SF-1 p.Gly146Ala variant identified by targeted gene panel. <sup>d</sup>Severity of the atypical phenotype of the external genitalia was classified according to (74).

Table 2. Additional gene variants identified in the DSD patients harbouring the *NR5A1*/SF-1 p.Gly146Ala variant.

Patient	Chromosome position	Gene (Name)	Variant	Type	dbSNP	Zygoty	Previously reported <sup>a</sup>
1	4:1807384	<i>FGFR3</i> (Fibroblast Growth Factor Receptor 3)	<b>c.1633_1634del; p.Cys545Hisfs*17</b>	frameshift deletion	ND	het	
	5:5232601	<i>ADAMTS16</i> (ADAM Metallopeptidase with Thrombospondin Type 1 Motif 16)	<b>c.1822_1823del; p.His608*</b>	stopgain	ND	het	
	19:7184641	<i>INSR</i> (Insulin Receptor)	<b>c.660_661del; p.Pro220Hisfs*4</b>	frameshift deletion	ND	het	
3	2:120989442	<i>GLI2</i> (GLI Family Zinc Finger 2)	c.3528G>T; p.Gln1176His	nonsynonymous SNV	rs139686081	het	
	8:60743055	<i>CHD7</i> (Chromodomain Helicase DNA Binding Protein 7)	<b>c.1623C&gt;A; p.His541Gln</b>	nonsynonymous SNV	ND	het	
	11:77181567 12:47865148	<i>MYO7A</i> (Myosin VIIA) <i>VDR</i> (Vitamin D Receptor)	<b>c.2882G&gt;A; p.Gly961Asp</b> <b>c.176C&gt;T; p.Thr59Ile</b>	nonsynonymous SNV nonsynonymous SNV	rs199575418 rs145002466	het het	
6	10:33330774	<i>NRP1</i> (Neuropilin 1)	c.182C>A; p.Pro61Gln	nonsynonymous SNV	ND	het	
8	2:48698724	<i>LHCGR</i> (Luteinizing Hormone/Choriogonadotropin Receptor)	<b>c.757T&gt;C; p.Ser253Pro</b>	nonsynonymous SNV	ND	hom	
9	11:32428517	<i>WT1</i> (WT1 Transcription Factor)	c.764T>A; p.Met255Lys	nonsynonymous SNV	rs377573993	het	
10	9:114275766	<i>COL27A1</i> (Collagen Type XXVII Alpha 1 Chain)	<b>c.3715C&gt;T; p.Arg1239Trp</b>	nonsynonymous SNV	rs143724625	het	
	15:41564270	<i>TYRO3</i> (TYRO3 Protein Tyrosine Kinase)	<b>c.666_667insCACTGCCTGCAGCCC CCTTCAACATCACCC; p.Ala223Hisfs*21</b>	frameshift insertion	ND	het	
11	16:984721	<i>SOX8</i> (SRY-Box Transcription Factor 8)	<b>c.676A&gt;C; p.Thr226Pro</b>	nonsynonymous SNV	ND	het	
12	7:75985941	<i>POR</i> (Cytochrome P450 Oxidoreductase)	<b>c.1679C&gt;T; p.Thr560Met</b>	nonsynonymous SNV	rs574694698	het	
	16:2114399	<i>PKD1</i> (Polycystin 1, Transient Receptor Potential Channel Interacting)	<b>c.2624C&gt;T; p.Pro875Leu</b>	nonsynonymous SNV	ND	het	
	16:30737182	<i>SRCAP</i> (Snf2 Related CREBBP Activator Protein)	<b>c.7142G&gt;A; p.Arg2381His</b>	nonsynonymous SNV	rs765139685	het	
	17:72123563	<i>SOX9</i> (SRY-Box Transcription Factor 9)	<b>c.710dup; p.Pro238Thrfs*14</b>	frameshift insertion	ND	het	Campomelic dysplasia (75)
13	X:67721837	<i>AR</i> (Androgen Receptor)	<b>c.2323C&gt;T; p.Arg775Cys</b>	nonsynonymous SNV	rs137852562	hemi	AIS (66)
14	11:77194460	<i>MYO7A</i> (Myosin VIIA)	<b>c.4259G&gt;A; p.Arg1420His</b>	nonsynonymous SNV	rs568337942	het	
	16:984739	<i>SOX8</i> (SRY-Box Transcription Factor 8)	<b>c.694A&gt;C; p.Lys232Gln</b>	nonsynonymous SNV	rs1596200787	het	

AIS, androgen insensitivity syndrome; Hemi, hemizygous; Het, heterozygous; Hom, homozygous; ND, not determined; POI, primary ovarian insufficiency.

Variants classified as pathogenic, likely pathogenic or as of unknown significance according to the ACMG (American College of Medical Genetics) are highlighted in bold.

<sup>a</sup>Previously associated disease to the specific variant identified in this work.

Figure 1. Algorithm of genetic workup. A. Mode of genetic analysis, e.g. panel and whole exome sequencing (WES). Three patients were identified with pathogenic variants in LHCGR, WT1 and AR by panel analysis and were not further analyzed by whole-exome sequencing (WES). B. Filtering algorithm of genetic data. Steps used for variant filtering after WES of eleven DSD patients harboring the NR5A1/SF-1 p.Gly146Ala variant are depicted (letters a to f). Final candidates and their possible impact are listed and characterized in Table 2 and Supplementary Table 3.




Figure 2. External genital phenotype of the 14 DSD patients harboring the NR5A1/SF-1 p.Gly146Ala variant shown with respect to their karyotype.




Figure 3. Genetic variants identified in 14 DSD patients harboring the *NR5A1*/SF-1 p.Gly146Ala variant illustrated with respect to the known pathways of male and female sex determination and differentiation. The scheme shows an overview of involved genes and their currently assumed relationship to sexual development. Genes with variants identified by whole exome sequencing in the patients have specific colors. In dark blue: candidate genes in patient 1; in brown: candidate genes in patient 3; in green: candidate genes in patient 6; in yellow: candidate genes in patient 8; in dark red: candidate genes in patient 9; in red: candidate genes in patient 10; in pink: candidate genes in patient 11; in light blue: candidate genes in patient 12; in purple: candidate genes in patient 13; in orange: candidate genes in patient 14; in dark grey: known genes involved in sexual development. Interrogation mark (?): function/timing/location is not clear; arrows: activation; inhibitors: inhibition; lines: interaction/partnership; dashed lines/arrows: hormone production.

